Search recent news
Search headlines, publishers, and topics in Factum’s recent news index.
Only the past seven days are included in this beta.
STAT+: Big drugmakers tell House committee they will halt clinical trials at some hospitals in China
Big drugmakers tell U.S. House committee they will halt clinical trials at some hospitals in China.
Opinion: The U.S. lost measles elimination status. The next Congress should help restore it
Infectious disease physician and STAT “ID Consult” columnist Krutika Kuppalli offers Congress a must-do list on measles.
Study raises doubts about combining vaccine, monoclonal antibody to protect against malaria
A monoclonal antibody holds promise in preventing malaria, but researchers found it interfered with a new vaccine when used in babies.
STAT+: Lawmakers want U.S. biotech to outcompete China
Lawmakers leading the congressional BIOTech Caucus say Washington needs to act in the sector — and fast:
STAT+: Peptide market poised to explode with new Hims and Noom launches
Two telehealth giants rolled out peptide programs this week after HHS made it easier for compounding pharmacies to offer drugs like BPC-157.
STAT+: MAHA PAC’s steakhouse spend
MAHA PAC's curious spending decisions, and a close look at what's next for the FDA.
National Academies report calls for faster decisions on publication retractions and corrections
The National Academies urged the scientific community to respond more aggressively to claims of errors or manipulated data in published research
STAT+: Epic defends competitive practices; promises AI access to records
In this edition of STAT Health Tech: EHR giant, Epic defends its competitive tactics, new data on AI and health care costs, and HLTH news.
STAT+: Pharmalittle: We’re reading about a Merck AI deal, China and the pharma supply chain, and more
Merck is entering a research collaboration with Isomorphic Labs, the AI drug designer built on a Nobel-winning technology
Sanders’ ‘Medicare for All’ plan accrues more liberal and moderate support in Congress
Sen. Bernie Sanders pushed back on assumptions that Trump would veto an expanded Medicare plan. “I am not absolutely certain that Trump would not sign it,” he said.
STAT+: Merck, Isomorphic Labs partner to develop oncology drug candidates
Merck and Isomorphic Labs said they are entering into a research collaboration to discover small molecule candidates in oncology.
STAT+: In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatment
Did the biotech company Erasca find a more potent, better-tolerated pan-RAS cancer drug than Revolution Medicines?
Opinion: STAT+: I’m a cardiologist. I’m a little puzzled about the blockbuster new study on deprescribing statins
STAT columnist Vishal Khetpal examines the STREAM trial and its findings about discontinuing use of statins.
STAT+: Before midterm losses, MAHA spent on itself instead of candidates
MAHA PAC spent more at a D.C. steakhouse than it did on the House race of a key ally.
STAT+: Epic Systems defends competitive practices, promises to let AI access its records
Executives from Epic, the largest electronics health records vendor, defended its competitive practices during a panel discussion at HLTH.
STAT+: Influential preventive services panel to meet for first time in more than a year
A task force, meeting after a long delay, will discuss coverage of treatments for cervical cancer, perinatal depression, and alcohol use.
STAT+: NIH to move last group of its research chimps to a sanctuary
The last chimpanzees owned by the U.S. government and still living in a laboratory will be moved to a sanctuary next year.
STAT+: 7 burning questions about the FDA’s post-Overton future
STAT tackles the most important questions about the FDA's uncertain future.
STAT+: The emerging winners and losers in the AI scribe market
In this edition of AI Prognosis: A closer look at how the AI scribe market is shaking out, news from the HLTH conference, and more
STAT+: Cassidy rejects Trump’s pick to lead NSF, saying he failed to ‘stand up for science’
Bill Cassidy's rejection of Jim O'Neill comes shortly after the White House pulled FDA commissioner nominee Heidi Overton.
STAT+: FDA discloses reasons for rejecting Summit drug
The FDA published its complete response letter to Summit Therapeutics explaining why it rejected the biotech's closely watched lung cancer drug:
STAT+: Pharmalittle: We’re reading about Overton FDA nomination being yanked, a Merck setback, and more
The Trump administration is pulling the nomination of Heidi Overton to lead the FDA over concerns she lacked support to get confirmed by the Senate
What redesigning medical school might look like
"I am asking whether every part of [the medical school] infrastructure needs to be bundled into the same four-year institution,” writes M.D./Ph.D. student Alex Serafini.
Opinion: STAT+: RFK Jr. has got to go
With Democrats riding a blue wave after the midterms, it’s time to impeach health secretary Robert F. Kennedy Jr., writes Paul Knoepfler.
Opinion: Maybe in-person four-year institutions aren’t the right approach to medical education
“Why do we have hundreds of institutions independently building parallel versions of the same pre-clerkship curriculum?”